4 Apr 2008 07:01
Oxford Instruments PLC04 April 2008 4 April 2008 Oxford Instruments plcPre-close Trading Update Oxford Instruments plc ("Oxford Instruments" or "the Group"), the advancedinstrumentation company, is today issuing a trading statement ahead of enteringits close period. The Board is confident that the Group's full year performance is in line withexpectations. Oxford Instruments' preliminary results for the year ended 31st March 2008 willbe released on Tuesday 10 June. Ends Enquiries: Oxford Instruments plc Tel: 01865 393 200Jonathan Flint Chief ExecutiveKevin Boyd Group Finance Director Hogarth Partnership Tel: 020 7357 9477Rachel HirstAndrew Jaques Notes to Editors Oxford Instruments designs, supplies and supports high-technology tools,processes and solutions with a focus on physical science, bioscience,environmental and industrial research and applications. It provides solutionsneeded to advance fundamental nanoscience research and its transfer intocommercial nanotechnology applications. Innovation has been the driving forcebehind Oxford Instruments' growth and success for over 40 years, and itsstrategy is to effect the successful commercialisation of these ideas bybringing them to market in a timely and customer-focused fashion. The first technology business to be spun out from Oxford University over fortyyears ago, Oxford Instruments is now a global company with over 1,300 staffworldwide and a listing on the London Stock Exchange (OXIG). Its objective is tobe the leading provider of new generation tools and systems for the PhysicalScience and Bioscience sectors. This involves the combination of core technologies in areas such as lowtemperature and high magnetic field environments, Nuclear Magnetic Resonance,X-ray electron and optical based metrology, and advanced growth, deposition andetching. Our products, expertise, and ideas address global issues such asenergy, environment, terrorism and health and are part of the next generation oftelecommunications, energy products, environmental measures, security devices,drug discovery and medical advances. This information is provided by RNS The company news service from the London Stock Exchange